Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesMohammad Alhadj Ali, Colin Dayan, Hina Shariff et al.|Science Translational Medicine|2017Cited by 215
Proinsulin peptide immunotherapy in type 1 diabetes:safety data of a first in new-onset type 1 diabetes phase 1b trialMohammad Alhadj Ali, Colin M Dayan, Yuk-Fun; id_orcid 0000-0002-8518-8756 Liu et al.|Research Portal (King's College London)|2015Cited by 0